4.5 Article

Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons

期刊

JOURNAL OF NEUROCHEMISTRY
卷 104, 期 4, 页码 1101-1115

出版社

WILEY
DOI: 10.1111/j.1471-4159.2007.05037.x

关键词

delta-like 1; differentiation; dopaminergic precursors; lentiviral vectors; shRNA; ventral midbrain progenitors

向作者/读者索取更多资源

Delta-like 1 (Dlk1), a member of the Delta/Notch protein family, is expressed in the mouse ventral midbrain (VM) as early as embryonic day 11.5 (E11.5) followed by exclusive expression in tyrosine 3-monooxygenase (TH) positive neurons from E12.5 onwards. To further elucidate the yet unknown function of DIk1 in VM neuron development, we investigated the effect of soluble Dlk1 protein as well as the intrinsic DIk1 function in the course of VM progenitor expansion and dopaminergic (DA) neuron differentiation in vitro. Dlk1 treatment during expansion increased DA progenitor proliferation and the proportion of NR4A2+ neurons expressing TH after differentiation, whereas Dlk1 treatment during the course of DA precursor differentiation did not alter TH+ neuron counts. In contrast, silencing of endogenously expressed Dlk1 prior to DA precursor differentiation partially prevented the expression of DA neuron markers, which was not accompanied with alteration of overall or local proliferation. Due to the latter finding in combination with the absence of Dlk1 negative DA neurons in differentiated cultures, we suggest that Dlk1 expression might have a permissive effect on DA neuron differentiation in vitro. The study presented here is the first publication identifying Dlk1 effects on ventral midbrain-derived DA precursor differentiation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Adipose-Derived Stem Cells from Type 2 Diabetic Rats Retain Positive Effects in a Rat Model of Erectile Dysfunction

Marlene Louise Quaade, Pratibha Dhumale, Simon Gabriel Comerma Steffensen, Hans Christian Beck, Eva Bang Harvald, Charlotte Harken Jensen, Lars Lund, Ditte Caroline Andersen, Soren Paludan Sheikh

Summary: The study found that diabetes does not appear to limit the effectiveness of autologous adipose stem cell therapy for treating erectile dysfunction (ED). Both diabetic and non-diabetic rats' adipose stem cells showed similar abilities in restoring erectile function and inducing genes related to endothelial function recovery.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Neurosciences

Mitochondrial and autophagy-lysosomal pathway polygenic risk scores predict Parkinson's disease

Mohammad Dehestani, Hui Liu, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Vikas Bansal, Thomas Gasser

Summary: This study assessed the predictive utility of PRS models constructed based on SNPs corresponding to two cardinal pathways in Parkinson's disease (PD). The results showed that these pathway PRS significantly predict PD risk, and mitochondrial PRS are significantly associated with later age of onset in PD patients.

MOLECULAR AND CELLULAR NEUROSCIENCE (2022)

Article Clinical Neurology

The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited

Cloe Domenighetti, Venceslas Douillard, Pierre-Emmanuel Sugier, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Sandeep Grover, Patrick May, Dheeraj R. Bobbili, Milena Radivojkov-Blagojevic, Peter Lichtner, Andrew B. Singleton, Dena G. Hernandez, Connor Edsall, Pierre-Antoine Gourraud, George D. Mellick, Alexander Zimprich, Walter Pirker, Ekaterina Rogaeva, Anthony E. Lang, Sulev Koks, Pille Taba, Suzanne Lesage, Alexis Brice, Jean-Christophe Corvol, Marie-Christine Chartier-Harlin, Eugenie Mutez, Kathrin Brockmann, Angela B. Deutschlander, Georges M. Hadjigeorgiou, Efthimos Dardiotis, Leonidas Stefanis, Athina Maria Simitsi, Enza Maria Valente, Simona Petrucci, Stefano Duga, Letizia Straniero, Anna Zecchinelli, Gianni Pezzoli, Laura Brighina, Carlo Ferrarese, Grazia Annesi, Andrea Quattrone, Monica Gagliardi, Hirotaka Matsuo, Akiyoshi Nakayama, Nobutaka Hattori, Kenya Nishioka, Sun Ju Chung, Yun Joong Kim, Pierre Kolber, Bart P. C. van de Warrenburg, Bastiaan R. Bloem, Jan Aasly, Mathias Toft, Lasse Pihlstrom, Leonor Correia Guedes, Joaquim J. Ferreira, Soraya Bardien, Jonathan Carr, Eduardo Tolosa, Mario Ezquerra, Pau Pastor, Monica Diez-Fairen, Karin Wirdefeldt, Nancy L. Pedersen, Caroline Ran, Andrea C. Belin, Andreas Puschmann, Emil Ygland Rodstrom, Carl E. Clarke, Karen E. Morrison, Manuela Tan, Dimitri KraincMD, Lena F. Burbulla, Matt J. Farrer, Rejko Kruger, Thomas Gasser, Manu Sharma, Nicolas Vince, Alexis Elbaz

Summary: This study conducted a large-scale independent replication of the interaction between HLA-DRB1 and smoking in Parkinson's disease. The valine at position 11 (V11) in HLA-DRB1 showed the strongest association with PD at the amino acid level. The results suggest an inverse association between genetically predicted smoking initiation and PD, particularly in individuals without the V11 variant. In silico predictions support this interaction pattern by showing the influence of V11 and smoking-induced modifications on binding affinity of alpha-synuclein.

MOVEMENT DISORDERS (2022)

Article Medicine, General & Internal

Trial of Prasinezumab in Early-Stage Parkinson's Disease

G. Pagano, K. I. Taylor, J. Anzures-Cabrera, M. Marchesi, T. Simuni, K. Marek, R. B. Postuma, N. Pavese, F. Stocchi, J. -P. Azulay, B. Mollenhauer, L. Lopez-Manzanares, D. S. Russell, J. T. Boyd, A. P. Nicholas, M. R. Luquin, R. A. Hauser, T. Gasser, W. Poewe, B. Ricci, A. Boulay, A. Vogt, F. G. Boess, J. Dukart, G. D'Urso, R. Finch, S. Zanigni, A. Monnet, N. Pross, A. Hahn, H. Svoboda, M. Britschgi, F. Lipsmeier, E. Volkova-Volkmar, M. Lindemann, S. Dziadek, S. Holiga, D. Rukina, T. Kustermann, G. A. Kerchner, P. Fontoura, D. Umbricht, R. Doody, T. Nikolcheva, A. Bonni

Summary: The study found that prasinezumab had no meaningful effect on global or imaging measures of Parkinson's disease progression and was associated with infusion reactions.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Multidisciplinary Sciences

Primary cilia and SHH signaling impairments in human and mouse models of Parkinson's disease

Sebastian Schmidt, Malte D. Luecken, Dietrich Truembach, Sina Hembach, Kristina M. Niedermeier, Nicole Wenck, Klaus Pfluegler, Constantin Stautner, Anika Boettcher, Heiko Lickert, Ciro Ramirez-Suastegui, Ruhel Ahmad, Michael J. Ziller, Julia C. Fitzgerald, Viktoria Ruf, Wilma D. J. van de Berg, Allert J. Jonker, Thomas Gasser, Beate Winner, Juergen Winkler, Daniela M. Vogt Weisenhorn, Florian Giesert, Fabian J. Theis, Wolfgang Wurst

Summary: Using single-cell RNA sequencing, the researchers found that neuronal cells from Parkinson's disease patients have altered primary cilia morphology and signaling, suggesting that cilia dysfunction may underlie the pathogenesis of Parkinson's disease.

NATURE COMMUNICATIONS (2022)

Article Clinical Neurology

Introduction to Gene Therapy

Thomas Gasser

Summary: After years of research and setbacks, gene therapies have achieved undeniable success by directly modifying genetic information on the DNA or RNA level. Both ex vivo strategies, manipulating patient cells outside the body, and in vivo approaches have been successful. In addition to gene supplementation, the use of the CRISPR-Cas9 system for altering nuclear DNA sequences and interfering with the transcriptional process on the RNA level can also be considered as gene therapies in a broad sense.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2023)

Review Clinical Neurology

The heterogeneity of Parkinson's disease

Ullrich Wuellner, Per Borghammer, Chi-un Choe, Ilona Csoti, Bjorn Falkenburger, Thomas Gasser, Paul Lingor, Peter Riederer

Summary: The heterogeneity of Parkinson's disease presents challenges for future research and therapeutic design. Various pathophysiological concepts and mechanisms, including alpha-synuclein misfolding, oxidative stress, and microbial agents, may contribute to the development of PD. The unresolved heterogeneity of PD has hindered previous clinical trials, highlighting the need for personalized therapeutic approaches.

JOURNAL OF NEURAL TRANSMISSION (2023)

Review Clinical Neurology

Genetic testing for Parkinson's disease in clinical practice

Thomas Gasser

Summary: The identification of disease-causing mutations or strong risk factors for Parkinson's disease in specific genes has led to a better understanding of disease pathogenesis. Many gene and mutation-specific targeted disease-modifying treatments are being developed and studied. Therefore, it is important to raise awareness and offer genetic testing to patients considering innovative trials.

JOURNAL OF NEURAL TRANSMISSION (2023)

Article Clinical Neurology

Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers

Pierre-Emmanuel Sugier, Elise A. Lucotte, Cloe Domenighetti, Matthew H. Law, Mark M. Iles, Kevin Brown, Christopher Amos, James D. McKay, Rayjean J. Hung, Mojgan Karimi, Delphine Bacq-Daian, Anne Boland-Auge, Robert Olaso, Jean-francois Deleuze, Fabienne Lesueur, Evgenia Ostroumova, Ausrele Kesminiene, Florent de Vathaire, Pascal Guenel, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Sandeep Grover, Patrick May, Dheeraj R. Bobbili, Milena Radivojkov-Blagojevic, Peter Lichtner, Andrew B. Singleton, Dena G. Hernandez, Connor Edsall, George D. Mellick, Alexander Zimprich, Walter Pirker, Ekaterina Rogaeva, Anthony E. Lang, Sulev Koks, Pille Taba, Suzanne Lesage, Alexis Brice, Jean-Christophe Corvol, Marie-Christine Chartier-Harlin, Eugenie Mutez, Kathrin Brockmann, Angela B. Deutschlaender, Georges M. Hadjigeorgiou, Efthimios Dardiotis, Leonidas Stefanis, Athina Maria Simitsi, Enza Maria Valente, Simona Petrucci, Letizia Straniero, Anna Zecchinelli, Gianni Pezzoli, Laura Brighina, Carlo Ferrarese, Grazia Annesi, Andrea Quattrone, Monica Gagliardi, Hirotaka Matsuo, Akiyoshi Nakayama, Nobutaka Hattori, Kenya Nishioka, Sun Ju Chung, Yun Joong Kim, Pierre Kolber, Bart P. C. van de Warrenburg, Bastiaan R. Bloem, Jan Aasly, Mathias Toft, Lasse Pihlstrom, Leonor Correia Guedes, Joaquim J. Ferreira, Soraya Bardien, Jonathan Carr, Eduardo Tolosa, Mario Ezquerra, Pau Pastor, Monica Diez-Fairen, Karin Wirdefeldt, Nancy Pedersen, Caroline Ran, Andrea C. Belin, Andreas Puschmann, Emil Ygland Roedstroem, Carl E. Clarke, Karen E. Morrison, Manuela Tan, Dimitri Krainc, Lena F. Burbulla, Matt J. Farrer, Rejko Kruger, Thomas Gasser, Manu Sharma, Therese Truong, Alexis Elbaz

Summary: By using genome-wide association studies, this study found that Parkinson's disease (PD) is genetically correlated with melanoma and prostate cancer, while it is inversely correlated with ovarian cancer. These findings suggest that pleiotropic genes contribute to the association between PD and specific cancers.

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease

Christos Koros, Kathrin Brockmann, Athina-Maria Simitsi, Anastasia Bougea, Hui Liu, Ann-Kathrin Hauser, Claudia Schulte, Stefanie Lerche, Ioanna Pachi, Nikolaos Papagiannakis, Roubina Antonelou, Athina Zahou, Isabel Wurster, Efthymia Efthymiopoulou, Ion Beratis, Matina Maniati, Marina Moraitou, Helen Michelakakis, Georgios Paraskevas, Sokratis G. Papageorgiou, Constantin Potagas, Dimitra Papadimitriou, Maria Bozi, Maria Stamelou, Thomas Gasser, Leonidas Stefanis

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Nir Giladi, Roy N. Alcalay, Gary Cutter, Thomas Gasser, Tanya Gurevich, Guenter U. Hoeglinger, Kenneth Marek, Claudio Pacchetti, Anthony H. Schapira, Clemens R. Scherzer, Tanya Simuni, Pascal Minini, S. Pablo Sardi, M. Judith Peterschmitt

Summary: The safety, efficacy, and target engagement of venglustat in early-stage Parkinson's disease patients with GBA1 variants were assessed. The study showed that venglustat had a satisfactory safety profile but did not show beneficial treatment effect compared with placebo. These findings suggest that glucosylceramide synthase inhibition with venglustat may not be a viable therapeutic approach for GBA1-associated Parkinson's disease.

LANCET NEUROLOGY (2023)

Letter Clinical Neurology

Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease

Christos Koros, Kathrin Brockmann, Athina-Maria Simitsi, Anastasia Bougea, Hui Liu, Ann-Kathrin Hauser, Claudia Schulte, Stefanie Lerche, Ioanna Pachi, Nikolaos Papagiannakis, Roubina Antonelou, Athina Zahou, Isabel Wurster, Efthymia Efthymiopoulou, Ion Beratis, Matina Maniati, Marina Moraitou, Helen Michelakakis, Georgios Paraskevas, Sokratis G. Papageorgiou, Constantin Potagas, Dimitra Papadimitriou, Maria Bozi, Maria Stamelou, Thomas Gasser, Leonidas Stefanis

MOVEMENT DISORDERS (2023)

Article Geriatrics & Gerontology

Evaluation of the Dementia Apraxia Test in Parkinson's Disease Patients

Daniela Renftle, Sara Becker, Kathrin Brockmann, Thomas Gasser, Katja Michaelis, Susanne Solbrig, Patricia Sulzer, Andreas Johnen, Inga Liepelt-Scarfone

Summary: This study evaluated the psychometric properties and validity of the Dementia Apraxia Test (DATE) in patients with Parkinson's disease. The results showed that DATE scores were associated with cognition and daily living function, but were confounded by motor impairment and age.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2022)

Meeting Abstract Clinical Neurology

Genetic correlation and potential causal relationship between inflammatory bowel disease and Parkinson's disease

S. Grover, E. Wacker, A. Kumar-Sreelatha, A. Elbaz, R. Kruger, T. Gasser, D. Ellinghaus, M. Sharma

MOVEMENT DISORDERS (2022)

Meeting Abstract Clinical Neurology

Genome-wide meta-analysis of Parkinson's disease identifies a novel chromosomal 22 locus: findings from the COURAGE-PD consortium

S. Grover, A. Kumar-Sreelatha, Z. Landoulsi, P. May, D. Bobbili, C. Domenighetti, C. Schulte, P. E. Sugier, A. Elbaz, R. Kruger, T. Gasser, M. Sharma

MOVEMENT DISORDERS (2022)

Article Biochemistry & Molecular Biology

Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study

Pei-Yang Gao, Ya-Nan Ou, Yi-Ming Huang, Zhi-Bo Wang, Yan Fu, Ya-Hui Ma, Qiong-Yao Li, Li-Yun Ma, Rui-Ping Cui, Yin-Chu Mi, Lan Tan, Jin-Tai Yu

Summary: Liver function may play a role in the progression of Alzheimer's disease. The study found that as AD progressed, certain liver function markers increased while others decreased. The relationship between liver function and CSF AD biomarkers indicates a potential mediation effect on cognition.

JOURNAL OF NEUROCHEMISTRY (2024)